Storm Riders Network - Into This World We're Thrown
RESOURCES. A resource for patients living with brain metastasis or leptomeningeal disease. Guiding Researchers & Advocates to Scientific Partnerships. Find a metastatic breast cancer clinical trial that is right for you. Click on the icon in top left menu to view a calendar of events including webinars, Continue reading “Find Events Near You ...
News & Publications - Storm Riders Network
Catch up on the latest news in breast cancer research. The links below will direct you to trusted sources including various peer-reviewed online publications, scientific papers, and academic articles. You can also search for articles within the following categories:
NCT04042480: A Study of SGN-CD228A in Advanced Solid Tumors
NCT04042480. Breast Cancer Type: HR+ & HER2-negative, Triple Negative. Hormone Mutations: ER+, PR+. Other Mutations: Breast Cancer Tissue: Recruitment Status: Recruiting. Phase 1.
NCT01255748: Registry Study for Radiation Therapy Outcomes
NCT01255748. Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative. Hormone Mutations: ER+, PR+. Other Mutations: Breast Cancer Tissue: Recruitment Status: Recruiting. Drug Category: Radiation Therapy.
Storm Riders Network
The Storm Riders Network is a one-stop tool for metastatic breast cancer (MBC) patients and survivors, co-survivors and caretakers. It is for anyone interested in learning more about the resources available to those riding out the storm that is breast cancer.
NCT05067972: A Study of PF-07260437 in Advanced or Metastatic …
NCT05067972. Breast Cancer Type: HR+ & HER2-negative, Triple Negative. Hormone Mutations: ER+, PR+. Other Mutations: B7-H4. Breast Cancer Tissue: Recruitment Status: Recruiting. Phase 1.
NCT05061537: Study of PF-07263689 in ... - Storm Riders Network
NCT05061537. Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative. Hormone Mutations: ER+, PR+. Other Mutations: Breast Cancer Tissue: Recruitment Status: Recruiting. Phase 1. Drug Category: Immunotherapy, Therapeutic Antibody.
NCT04606446: Study of PF-07248144 in Advanced or Metastatic …
NCT04606446. Breast Cancer Type: HR+ & HER2-negative. Hormone Mutations: ER+. Other Mutations: Breast Cancer Tissue: Recruitment Status: Recruiting. Phase 1. Drug Category: Endocrine (Hormone Therapy, Serine-Threonine Kinase Inhibitor, Misc Inhibitor.
NCT04646759: Fulvestrant or Capecitabine Combined With …
NCT04646759. Breast Cancer Type: HER2+. Hormone Mutations: ER+, PR+. Other Mutations: Breast Cancer Tissue: Recruitment Status: Recruiting. Phase 3. Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy, Chemotherapy.
NCT05394675: A Study of DS-9606a in Patients With Advanced …
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative. Hormone Mutations: ER+, PR+. Other Mutations: Breast Cancer Tissue: Recruitment Status: Recruiting. Phase 1. Drug Category: Therapeutic Antibody.